The mixed picture exhibits an injection pen for Eli Lilly’s weight reduction drug Zepbound and a field of Mounjaro, an injectable tirzepatide drug. Yurpeak might be obtainable as a weekly pre-filled injector pen, much like the Mounjaro Kwikpen. File | Picture credit score: Reuters
Eli Lilly has signed a take care of Cipla that can permit the Indian drugmaker to promote its blockbuster weight reduction drug beneath a separate model within the nation, the businesses introduced on Thursday (23 October 2025).
Underneath the settlement, Lilly will manufacture the drug and Cipla will promote it beneath the model identify Yurpeek, in line with the drug corporations.
Yurpeak, like Lilly’s Mounjaro Kwikpen, comes as a once-a-week prefilled syringe pen, permitting healthcare suppliers to customise therapy plans to suit particular person affected person wants.
The drug might be obtainable in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and might be priced the identical as Mounjaro.
Lilly started promoting its diabetes and weight problems drug Munjaro in 2.5-milligram and 5-milligram vials in India in late March, and later acquired approval for its QuikPen gadget from India’s drug regulator in June. Gross sales of the drug greater than doubled inside months of its launch.
Tirzepatide belongs to a category of therapies referred to as GLP-1 receptor agonists, which management blood sugar ranges, gradual digestion, and make you are feeling fuller longer.
